Explore the words cloud of the HD4HF project. It provides you a very rough idea of what is the project "HD4HF" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-12-01 to 2019-05-31|
Take a look of project's partnership.
This project supports the market introduction of the Heart Damper (HD), a very innovative implantable cardiac device, intended to provide a simple, quick and cost-effective solution to treat patients affected by systolic heart failure.
Heart Failure (HF) is a growing epidemic and a major public health issue: only in EU and US it affects today about 15 million people, with an expected growth of about 38% by 2030. 2 million of these patients are affected by advanced heart failure: a phase in which the pharmacological therapies alone are no longer sufficient to manage the symptoms. Late stage treatments, such as Ventricular Assist Device (VAD) or Total Artificial Heart (TAH) are indeed inevitably associated with high risk of rejection and low quality of life. HF has no actual cure apart from heart transplantation, which is very rare and impossible for people over 65 (80% of HF patients). In addition, HF has a significant social cost, as it doesn’t affect only the individual patient, but also his family and his community. In the US, for example, the costs related to the loss of work and household productivity are estimated at $ 8.2 billion/year (by 2030, $12.3 billion/year).
The Heart Damper, a minimally invasive cardiac device, will make it possible to give patients a longer and better life expectancy, independently from their age, at the same time reducing the staggering associated healthcare costs. Designed to be stably fitted into the left ventricle by a simple transapical surgical procedure, once implanted it moves upwards exploiting the residual contractile cacapacity of the heart, without any need of external energy sources. The device is protected by a patent fully owned by Eucardia, which has been granted in Europe, US and other major countries worldwide.
The SME 1 Instrument will enable Eucardia to assess in detail the technical feasibility and economic viability of its innovation, in order to ease HD market penetration, in respect of HF market segment.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HD4HF" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HD4HF" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More
IOT and cloud computing for online medical analysis service platformRead More